Civic AI
Procurement intelligence
Federal contract award
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · Department of Health and Human Services
- Value
- $1,097,981
- Start
- Sep 15, 2022
- End
- Jun 14, 2026
- Action date
- Apr 8, 2026
- PIID
- 75N91022F00002
- Status
- completed
- NAICS
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Place of performance
- HOUSTON, TX
- Award type
- DELIVERY ORDER
Description
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Need modifications, related awards, and vendor peers? Open the full award workspace.